Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN

被引：0
|
作者：
Zheng, Y. [1 ]
Jin, D. [1 ]
Guan, Y. [1 ]
Ozguroglu, M. [2 ]
Trukhin, D. [3 ]
Poltoratskiy, A. [4 ]
Chen, Y. [5 ]
Havel, L. [6 ]
Hochmair, M. [7 ]
Paz-Ares, L. [8 ,9 ]
Jiang, H. [10 ]
Armstrong, J. [11 ]
Chen, C. [1 ]
Liu, Y. H. [10 ]
Roskos, L. [1 ]
机构：
[1] Astrazeneca, San Francisco, CA USA
[2] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey
[3] Odessa Reg Oncol Dispensary, Odessa, Ukraine
[4] Petrov Res Inst Oncol, St Petersburg, Russia
[5] Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA
[6] Charles Univ Prague, Fac Med 1, Thomayer Hosp, Prague, Czech Republic
[7] Krankenhaus Nord, Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria
[8] Univ Complutense, Hosp Univ 12 Octubre, H120 Cnio Lung Canc Unit, Madrid, Spain
[9] Ciberonc, Madrid, Spain
[10] Astrazeneca, Gaithersburg, MD USA
[11] Astrazeneca, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
CASPIAN; population pharmacokinetics; Durvalumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P48.21
引用
收藏
页码：S508 / S508
页数：1
相关论文
共 15 条
  • [1] First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN
    Reinmuth, N.
    Garassino, M. C.
    Trukhin, D.
    Hochmair, M. J.
    Ozguroglu, M.
    Havel, L.
    Goldman, J.
    Chen, Y.
    Losonczy, G.
    Spinnato, F.
    Conev, N.
    Bar, J.
    Broadhurst, H.
    Byrne, N.
    Jiang, H.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S500 - S500
  • [2] Durvalumab ± Tremelimumab plus Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN
    Garassino, M. C.
    Shrestha, Y.
    Xie, M.
    Lai, Z.
    Spencer, S.
    Dalvi, T.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S939 - S939
  • [3] Assessment of the Efficacy and Safety of Durvalumab Associated with Platinum-Etoposide in Previously Untreated ES-SCLC in Brazil
    Lopes, D.
    Zukin, M.
    Calabrich, A.
    Cordeiro de Lima, V.
    Corassa, M.
    Gossling, G.
    Gomes de Jesus, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S376 - S376
  • [4] LUMINANCE: A Phase IIIb Study of Durvalumab plus Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)
    Reinmuth, N.
    DeMarinis, F.
    Leighl, N.
    Sadow, S.
    Davey, K.
    Ozguroglu, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S547 - S547
  • [5] Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
    Paz-Ares, L.
    Chen, Y.
    Reinmuth, N.
    Hotta, K.
    Trukhin, D.
    Statsenko, G.
    Hochmair, M. J.
    Ozguroglu, M.
    Ji, J. H.
    Voitko, O.
    Poltoratskiy, A.
    Ponce, S.
    Verderame, F.
    Havel, L.
    Bondarenko, I.
    Kazarnowicz, A.
    Losonczy, G.
    Conev, N. V.
    Armstrong, J.
    Byrne, N.
    Shire, N.
    Jiang, H.
    Goldman, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S7 - S8
  • [6] Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
    Chen, Yuanbin
    Paz-Ares, Luis
    Reinmuth, Niels
    Garassino, Marina Chiara
    Statsenko, Galina
    Hochmair, Maximilian J.
    Oezgueroglu, Mustafa
    Verderame, Francesco
    Havel, Libor
    Losonczy, Gyoergy
    Conev, Nikolay, V
    Hotta, Katsuyuki
    Ji, Jun Ho
    Spencer, Stuart
    Dalvi, Tapashi
    Jiang, Haiyi
    Goldman, Jonathan W.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 3 (06):
  • [7] First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
    Hotta, Katsuyuki
    Nishio, Makoto
    Saito, Haruhiro
    Okamoto, Isamu
    Nakahara, Yasuharu
    Hayashi, Hidetoshi
    Hayama, Manabu
    Laud, Peter
    Jiang, Haiyi
    Paz-Ares, Luis
    Azuma, Koichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (06) : 1073 - 1082
  • [8] First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
    Katsuyuki Hotta
    Makoto Nishio
    Haruhiro Saito
    Isamu Okamoto
    Yasuharu Nakahara
    Hidetoshi Hayashi
    Manabu Hayama
    Peter Laud
    Haiyi Jiang
    Luis Paz-Ares
    Koichi Azuma
    International Journal of Clinical Oncology, 2021, 26 : 1073 - 1082
  • [9] Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study
    Goldman, Jonathan W.
    Garassino, Marina Chiara
    Chen, Yuanbin
    Ozguroglu, Mustafa
    Dvorkin, Mikhail
    Trukhin, Dmytro
    Statsenko, Galina
    Hotta, Katsuyuki
    Ji, Jun Ho
    Hochmair, Maximilian J.
    Voitko, Oleksandr
    Havel, Libor
    Poltoratskiy, Artem
    Losonczy, Gyorgy
    Reinmuth, Niels
    Patel, Nikunj
    Laud, Peter J.
    Shire, Norah
    Jiang, Haiyi
    Paz-Ares, Luis
    LUNG CANCER, 2020, 149 : 46 - 52
  • [10] Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer
    Abegesah, Aburough
    Oh, Do-Youn
    Lim, Kyoungsoo
    Fan, Chunling
    Chen, Cecil
    Kim, Chong
    Wang, Julie
    Xynos, Ioannis
    Zotkiewicz, Magdalena
    Ren, Song
    Phipps, Alex
    Gibbs, Megan
    Zhou, Diansong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
12